Trending now
Results for
Results for
Create your own feed
Innate courting success despite split decision on milestone in Astrazeneca deal? Jury’s out
Share
Under pressure, Pfizer, Moderna (and soon AstraZeneca) publish COVID-19 vaccine protocols
Chutes & Ladders—Olema Oncology brings on AstraZeneca vet Bohen as CEO
So once AstraZeneca publishes their #COVID19 trial design, that has to make this the industry standard. Everyone has to follow through, right?
These growing calls for transparency have led Moderna, swiftly followed by Pfizer/BioNTech (and a pledge from AstraZeneca), to release their protocols this week, all of which are in the later stages of testing and likely to see datain the coming months.
$AZN: AstraZeneca: LYNPARZA improved median time patients lived without disease progression to over four and half...
$AZN: AstraZeneca: IMFINZI Demonstrated unprecedented survival in unresectable stage III non-small cell lung cancer...
We're looking for the AstraZeneca protocol 'shortly', while experts debate merits of Pfizer v Moderna
AstraZeneca’s Imfinzi Trial Shows Survival In Lung Cancer Patients $AZN
Loading
Drug giant AstraZeneca said it had paused a trial of its coronavirus vaccine because of an unexplained illness in one of the volunteers. It’s a standard precaution, meant to ensure experimental vaccines don’t cause serious reactions among volunteers.
BREAKING: AstraZeneca's #Covid19 vaccine trials have been paused as the company investigates a serious adverse event the occurred in the UK. Not clear if the unexplained illness is linked to the vaccine, or what it was.
JUST IN: AstraZeneca has put its phase three vaccine trial on hold due to an unexplained illness in a participant
Breaking News: A major coronavirus vaccine trial was halted because of a serious adverse reaction in a participant, the pharmaceutical company AstraZeneca said.
President @realDonaldTrump just announced that AstraZeneca's vaccine has reached Phase 3 clinical trials!
First human trial of AstraZeneca COVID-19 vaccine shows promise
JUST IN: A coronavirus vaccine the University of Oxford is developing with AstraZeneca Plc showed promising results in early human testing, a sign of progress in the high-stakes pursuit of a shot to defeat the pathogen
This is what our government is paying to develop a COVID19 vaccine: - $1.2 billion to AstraZeneca - $483 million to Moderna - $500 million to Johnson & Johnson - $30 million to Sanofi Once a vaccine is approved by the FDA, it must be available to all for free. No profiteering.
AstraZeneca and the University of Oxford are teaming up to develop and manufacture a vaccine for coronavirus with the aim of building capacity to produce 100m doses by the end of the year if it is shown to be effective
Loading